

Faxed prescriptions will only be accepted from a prescriber. Patients must bring an original prescription to the pharmacy, and cannot fax these referral forms to Senderra.



# SENDERRA

Specialty Pharmacy

3712 E. Plano Parkway, Ste. 200  
Plano, TX 75074

This prescription form is to be sent & received via fax

**Asthma/Respiratory  
Enrollment Form**

**Physician Offices Call:  
855-460-7928**

**Fax: 888-777-5645**

**Prescriber:**

**NPI:**

**Supervising Physician:**

**NPI:**

**Address:**

**Tax ID:**

**Phone:**

**Fax:**

**Contact:**

### PATIENT INFORMATION

Name: \_\_\_\_\_  M  F  Trans M  Trans F  Other DOB: \_\_\_\_/\_\_\_\_/\_\_\_\_ SS#: \_\_\_\_-\_\_\_\_-\_\_\_\_

Street: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ ZIP: \_\_\_\_\_

Phone: \_\_\_\_\_ Alt. Phone: \_\_\_\_\_  English  Spanish  Other: \_\_\_\_\_ Wt.: \_\_\_\_\_ Ht.: \_\_\_\_\_

### PRESCRIPTION

Has the patient received a loading dose/starter kit?  Yes Start Date: \_\_\_\_/\_\_\_\_/\_\_\_\_  No Ship to:  Patient's Home  Doctor's Office  Other: \_\_\_\_\_

Drug	Strength	Directions & Quantity			Refills
Actemra®	<input type="checkbox"/> 162 mg ACTPen®	<input type="checkbox"/> Inject 162 mg SQ every week (Quantity: 4)			
	<input type="checkbox"/> 162 mg Pre-filled Syringe				
Acthar® Gel	<input type="checkbox"/> 5 mL multi-dose vial	Dose: _____	Route of Administration: _____	Schedule/Frequency: _____	Quantity of Vials: _____
		<input type="checkbox"/> Units <input type="checkbox"/> mL	<input type="checkbox"/> IM <input type="checkbox"/> SQ	_____	_____
Dupixent®	<input type="checkbox"/> 200 mg Pre-filled Syringe	<input type="checkbox"/> INITIAL: Inject 400 mg SQ (two 200 mg injections) at week 0 (Quantity: 2)			
	<input type="checkbox"/> 200 mg Pen	<input type="checkbox"/> MAINTENANCE: Inject 200 mg SQ every other week starting at day 15 (Quantity: 2)			
	<input type="checkbox"/> 300 mg Pre-filled Syringe	<input type="checkbox"/> INITIAL: Inject 600 mg SQ (two 300 mg injections) at week 0 (Quantity: 2)			
Dupixent®	<input type="checkbox"/> 300 mg Pen	<input type="checkbox"/> MAINTENANCE: Inject 300 mg SQ every other week starting at day 15 (Quantity: 2)			
		<input type="checkbox"/> Inject 300 mg SQ every other week (Quantity: 2) ***Dosing intended for chronic rhinosinusitis with nasal polyposis (CRSwNP)***			
Nucala®	<input type="checkbox"/> 100 mg Vial	<input type="checkbox"/> Inject 100 mg SQ once every 4 weeks (Quantity: 1)			
	<input type="checkbox"/> 100 mg Autoinjector				
Purified Cortrophin® Gel	<input type="checkbox"/> 5 mL multi-dose vial	Dose: _____	Route of Administration: _____	Schedule/Frequency: _____	Quantity of Vials: _____
		<input type="checkbox"/> Units <input type="checkbox"/> mL	<input type="checkbox"/> IM <input type="checkbox"/> SQ	_____	_____

### MEDICAL INFORMATION

**\*\*\*PLEASE FAX COPY OF PRESCRIPTION/MEDICAL CARD, FRONT AND BACK, AS WELL AS ANY CLINICAL NOTES REGARDING THERAPY\*\*\***

PREVIOUS THERAPIES:	Tried & Failed (Duration):	Not Tolerated:	Therapy Contraindications:
<input type="checkbox"/> Short-acting beta-agonist (SABA): _____	<input type="checkbox"/> (_____)	<input type="checkbox"/>	_____
<input type="checkbox"/> Inhaled corticosteroids with long-acting beta-agonist (ICS/LABA) combination therapy: _____	<input type="checkbox"/> (_____)	<input type="checkbox"/>	_____
<input type="checkbox"/> Inhaled corticosteroids (without LABA): _____	<input type="checkbox"/> (_____)	<input type="checkbox"/>	_____
<input type="checkbox"/> Long-acting muscarinic antagonist (LAMA): _____	<input type="checkbox"/> (_____)	<input type="checkbox"/>	_____
<input type="checkbox"/> Leukotriene receptor antagonist (LTRA): _____	<input type="checkbox"/> (_____)	<input type="checkbox"/>	_____
<input type="checkbox"/> Oral/injectable corticosteroids: _____	<input type="checkbox"/> (_____)	<input type="checkbox"/>	_____
<input type="checkbox"/> Other controller (specify): _____	<input type="checkbox"/> (_____)	<input type="checkbox"/>	_____

IgE Level: \_\_\_\_\_ Date: \_\_\_\_/\_\_\_\_/\_\_\_\_ Number of severe exacerbations past 12 months: \_\_\_\_\_

Eosinophil levels: \_\_\_\_\_ cells/mL Date: \_\_\_\_/\_\_\_\_/\_\_\_\_  Patient has moderate to severe asthma that requires add-on maintenance treatment

Patient has had prior sinus surgery Date: \_\_\_\_/\_\_\_\_/\_\_\_\_  Patient is not a candidate for surgery Rationale: \_\_\_\_\_

**Date of Diagnosis:** \_\_\_\_/\_\_\_\_/\_\_\_\_ **Allergies:** \_\_\_\_\_

<input type="checkbox"/> D86.9 Sarcoidosis, unspecified	<input type="checkbox"/> J32.9 Chronic sinusitis, unspecified	<input type="checkbox"/> J33.0 Polyp of Nasal Cavity
<input type="checkbox"/> J33.9 Nasal Polyp, unspecified	<input type="checkbox"/> J45.40 Moderate Persistent Asthma, uncomplicated	<input type="checkbox"/> J45.41 Moderate Persistent Asthma w/ acute exacerbation
<input type="checkbox"/> J45.50 Severe Persistent Asthma, uncomplicated	<input type="checkbox"/> J45.51 Severe Persistent Asthma w/ acute exacerbation	<input type="checkbox"/> M34.81 Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
<input type="checkbox"/> Other: _____		

### Additional Clinical Information:

### INJECTION TRAINING

Patient has received pen and injection training  Physician's office to provide injection training  Senderra to coordinate injection training

### PRESCRIBER SIGNATURE

**To Prescriber:** By signing this form and utilizing our services, you are also authorizing Senderra to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies, and co-pay assistance foundations.

**Prescriber:** \_\_\_\_\_

**Date:** \_\_\_\_/\_\_\_\_/\_\_\_\_

### CONFIDENTIALITY NOTICE

**IMPORTANT:** This fax is intended to be delivered only to the named addressee. It contains material that is confidential, proprietary or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.